Application 761034
- Type
- BLA
- Sponsor
- GENENTECH INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | TECENTRIQ | ATEZOLIZUMAB | INJECTABLE;INJECTION | 1200MG/20ML | No | No |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-917 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
| 50242-918 | TECENTRIQ | atezolizumab | Genentech, Inc. | BLA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 85999 | SUPPL | 2026-05-21 |
| 85973 | SUPPL | 2026-05-19 |
| 85964 | SUPPL | 2026-05-19 |
| 85940 | SUPPL | 2026-05-18 |
| 85904 | SUPPL | 2026-05-13 |
| 84202 | SUPPL | 2025-11-18 |
| 84190 | SUPPL | 2025-11-18 |
| 83649 | SUPPL | 2025-10-03 |
| 83144 | SUPPL | 2025-08-20 |
| 83136 | SUPPL | 2025-08-19 |
| 78255 | SUPPL | 2024-04-25 |
| 78208 | SUPPL | 2024-04-23 |
| 74252 | SUPPL | 2023-05-15 |
| 74251 | SUPPL | 2023-05-15 |
| 74245 | SUPPL | 2023-05-15 |
| 74244 | SUPPL | 2023-05-15 |
| 72864 | SUPPL | 2022-12-12 |
| 72857 | SUPPL | 2022-12-12 |
| 72856 | SUPPL | 2022-12-12 |
| 72786 | SUPPL | 2022-12-05 |
| 72785 | SUPPL | 2022-12-05 |
| 69966 | SUPPL | 2022-01-25 |
| 69965 | SUPPL | 2022-01-25 |
| 69960 | SUPPL | 2022-01-25 |
| 69075 | SUPPL | 2021-10-22 |
| 69038 | SUPPL | 2021-10-20 |
| 68960 | SUPPL | 2021-10-12 |
| 68959 | SUPPL | 2021-10-12 |
| 68910 | SUPPL | 2021-10-07 |
| 67077 | SUPPL | 2021-04-16 |
| 67076 | SUPPL | 2021-04-16 |
| 67055 | SUPPL | 2021-04-14 |
| 66292 | SUPPL | 2021-02-18 |
| 66291 | SUPPL | 2021-02-18 |
| 66290 | SUPPL | 2021-02-18 |
| 66289 | SUPPL | 2021-02-18 |
| 66288 | SUPPL | 2021-02-18 |
| 66287 | SUPPL | 2021-02-18 |
| 66274 | SUPPL | 2021-02-18 |
| 66273 | SUPPL | 2021-02-18 |
| 66272 | SUPPL | 2021-02-18 |
| 66271 | SUPPL | 2021-02-18 |
| 66270 | SUPPL | 2021-02-18 |
| 66269 | SUPPL | 2021-02-18 |
| 66268 | SUPPL | 2021-02-18 |
| 65834 | SUPPL | 2021-01-06 |
| 65728 | SUPPL | 2020-12-23 |
| 65727 | SUPPL | 2020-12-23 |
| 65726 | SUPPL | 2020-12-23 |
| 65724 | SUPPL | 2020-12-23 |
| 65684 | SUPPL | 2020-12-22 |
| 65683 | SUPPL | 2020-12-22 |
| 65220 | SUPPL | 2020-11-13 |
| 65219 | SUPPL | 2020-11-13 |
| 65188 | SUPPL | 2020-11-12 |
| 64815 | SUPPL | 2020-10-02 |
| 64814 | SUPPL | 2020-10-02 |
| 64785 | SUPPL | 2020-10-01 |
| 64154 | SUPPL | 2020-07-31 |
| 64150 | SUPPL | 2020-07-30 |
| 63388 | SUPPL | 2020-06-02 |
| 63353 | SUPPL | 2020-05-29 |
| 63352 | SUPPL | 2020-05-29 |
| 63106 | SUPPL | 2020-05-19 |
| 63085 | SUPPL | 2020-05-18 |
| 61146 | SUPPL | 2019-12-04 |
| 61140 | SUPPL | 2019-12-03 |
| 61139 | SUPPL | 2019-12-03 |
| 58612 | SUPPL | 2019-05-08 |
| 58611 | SUPPL | 2019-05-08 |
| 58587 | SUPPL | 2019-05-07 |
| 58585 | SUPPL | 2019-05-07 |
| 58070 | SUPPL | 2019-03-25 |
| 58028 | SUPPL | 2019-03-19 |
| 56826 | SUPPL | 2019-03-12 |
| 57938 | SUPPL | 2019-03-08 |
| 57936 | SUPPL | 2019-03-08 |
| 56640 | SUPPL | 2018-12-06 |
| 54851 | SUPPL | 2018-07-06 |
| 54797 | SUPPL | 2018-07-06 |
| 54739 | SUPPL | 2018-07-02 |
| 54720 | SUPPL | 2018-06-28 |
| 54667 | SUPPL | 2018-06-21 |
| 54649 | SUPPL | 2018-06-21 |
| 54633 | SUPPL | 2018-06-20 |
| 54614 | SUPPL | 2018-06-20 |
| 54008 | SUPPL | 2018-05-03 |
| 53999 | SUPPL | 2018-05-03 |
| 52989 | SUPPL | 2018-03-15 |
| 52965 | SUPPL | 2018-03-14 |
| 48094 | SUPPL | 2017-04-24 |
| 43552 | ORIG | 2016-06-21 |
| 24538 | ORIG | 2016-06-21 |
| 10662 | ORIG | 2016-05-19 |
| 40639 | ORIG | 2016-05-18 |